Roche delivered a head-to-head win for its next-generation KRAS G12C inhibitor at ESMO, cutting the risk of death by 44% in previously treated mutant non-small cell lung cancer versus comparable drugs targeting the same KRAS variant from Amgen and Bristol Myers. The readout intensifies competition in KRAS-targeted oncology as companies seek to establish sequencing advantages. The result is likely to influence the way clinicians select KRAS G12C therapies after progression and how payers interpret comparative survival outcomes across this class. With additional data typically expected at future conferences, Roche’s magnitude signal sets an immediate benchmark for rivals developing second-generation KRAS candidates.